Drug Trial Radar · NCT07320716
Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
179
Planned (sponsor's estimate)
Start
Feb 6, 2026
Primary completion
Oct 16, 2028
Study completion Oct 16, 2028
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jan 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 26 months, up to 55 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The current study is a follow-up to 2 previous parent studies, a dose-selection study with 3 different dose-levels of the altSonflex1-2-3 vaccine in a schedule of 3 vaccinations (H06\_01TP study \[NCT05073003, 212149\]) and a study with an alternate 2 vaccination schedule H06\_02TP study \[NCT06663436, 219449\]). The current study aims to assess the longevity of the immune response to the selected dose of the altSonflex1-2-3 vaccine 1, 2, and 3 years after the last vaccination in African children. The study involves no new vaccinations but will collect immunogenicity blood samples from participants.
Conditions
- Diarrhoea
Interventions
AltSonflex1-2-3Biological
No intervention is administered in this extension study. The selected dose of altSonflex1-2-3 vaccine was administered intramuscularly in the participants' thigh during the H06\_01TP (212149) parent study on Day 1, Day 85, and Day 253; or on Day 1 and Day 169 during the H06\_02TP (219449) study.
MenveoBiological
No intervention is administered in this extension study. The Menveo vaccine was administered intramuscularly in the participants' thigh on Day 1 and Day 85 during the H06\_01TP (212149) parent study.
Infanrix hexaBiological
No intervention is administered in this extension study. The Infanrix hexa vaccine was administered intramuscularly in the participants' thigh on Day 281 during the H06\_01TP (212149) study; or on Day 169 during the H06\_02TP (219449) parent study.
TYPHIBEVBiological
No intervention is administered in this extension study. The TYPHIBEV vaccine was administered intramuscularly in the participants' thigh on Day 1 during the H06\_02TP (219449) parent study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Anti-serotype specific Shigella lipopolysaccharide (LPS)/O-antigen (OAg) serum immunoglobulin G (IgG), as measured by GVGH enzyme-linked immunosorbent assay . (ELISA)Time frame: At Visit 1 of the current study (12 months after last vaccination in the parent studies)
- Anti-serotype specific Shigella LPS/OAg serum IgG, as measured by GVGH ELISATime frame: At Visit 2 of the current study (24 months after last vaccination in the parent studies)
- Anti-serotype specific Shigella LPS/OAg serum IgG, as measured by GVGH ELISATime frame: At Visit 3 of the current study (36 months after last vaccination in the parent studies)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Kericho, Kenya · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.